Lung airway epithelial cell (LAEC)

Lung airway epithelial cells constitute the primary physical and biological barrier of the respiratory tract, extending from the trachea to the terminal bronchioles. These cells are specialized into various types, including ciliated, goblet, basal, and club cells, which collectively maintain homeostasis through mucociliary clearance and the secretion of immunomodulatory factors (Gohy et al., 2019, European Respiratory Review). In pathological states such as asthma, COPD, and cystic fibrosis, the airway epithelium undergoes significant remodeling, characterized by goblet cell metaplasia and impaired barrier function (Whitsett and Alenghat, 2015, Nature). While the lung airway epithelial cell is a cellular entity rather than a single molecular target, it expresses critical therapeutic targets like the Beta-2 adrenergic receptor and the CFTR protein (Hollenhorst et al., 2011, Physiological Reviews). Pharmacological intervention often aims to restore epithelial integrity or modulate the activity of these surface receptors to alleviate respiratory distress and inflammation (Hoffmann et al., 2020, Cell).

Other names

Airway epitheliumRespiratory epithelial cellBronchial epithelial cellTracheal epithelial cellAirway surface epithelial cell

Drugs do not target the cell as a whole but rather specific proteins expressed on these cells. For example, beta-2 adrenergic agonists (e.g., Albuterol) activate receptors on the epithelial surface to influence ciliary beat frequency and fluid secretion, while CFTR potentiators (e.g., Ivacaftor) target the Cystic Fibrosis Transmembrane Conductance Regulator to restore ion transport (Hollenhorst et al., 2011, Physiological Reviews). Biologics like Tezepelumab target epithelial-derived cytokines (TSLP) to reduce airway inflammation (Corren et al., 2017, NEJM).